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Abstract.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)
plays critical roles in host cell entry. Non-synonymous substitutions affecting S are not
uncommon and have become fixed in a number of SARS-CoV-2 lineages. A subset of
such mutations enable escape from neutralizing antibodies or are thought to enhance
transmission through mechanisms such as increased affinity for the cell entry receptor,
angiotensin-converting enzyme 2 (ACE2). Independent genomic surveillance programs
based in New Mexico and Louisiana contemporaneously detected the rapid rise of
numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The
variant was first detected in the US on October 23, yet between 01 Dec 2020 and 19
Jan 2021 it rose to represent 27.8% and 11.3% of all SARS-CoV-2 genomes
sequenced from Louisiana and New Mexico, respectively. Q677P cases have been
detected predominantly in the south central and southwest United States; as of 03 Feb
2021, GISAID data show 499 viral sequences of this variant from the USA. Phylogenetic
analyses revealed the independent evolution and spread of at least six distinct Q677H
sub-lineages, with first collection dates ranging from mid-August to late November 2020.
Four 677H clades from clade 20G (B.1.2), 20A (B.1.234), and 20B (B.1.1.220, and
B.1.1.222) each contain roughly 100 or fewer sequenced cases, while a distinct pair of
clade 20G clusters are represented by 754 and 298 cases, respectively. Although
sampling bias and founder effects may have contributed to the rise of S:677
polymorphic variants, the proximity of this position to the polybasic cleavage site at the
S1/S2 boundary are consistent with its potential functional relevance during cell entry,
suggesting parallel evolution of a trait that may confer an advantage in spread or
transmission. Taken together, our findings demonstrate simultaneous convergent
evolution, thus providing an impetus to further evaluate S:677 polymorphisms for effects
on proteolytic processing, cell tropism, and transmissibility.
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Introduction.
In mid-December 2020, the United Kingdom reported a SARS-CoV-2 variant termed
B.1.1.7 (20I/501Y.V1) that exhibited a rapid increase in its range and incidence
following its initial detection in November (Andrew Rambaut, Nick Loman, Oliver Pybus,
Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L
Robertson, Erik Volz, COVID-19 Genomics Consortium UK (CoG-UK), 2020; Volz,
Mishra, et al., 2021). Since then, additional “variants of concern” have emerged, namely
lineages B.1.351 (20H/501Y.V2) from South Africa (Tegally et al., 2020) and P.1
(20J/501Y.V3) and P.2 from Brazil (Voloch et al., 2020; Faria et al., 2021; Naveca, da
Costa, et al., 2021; Sabino et al., 2021). A key concern is that certain polymorphisms
may enhance SARS-CoV-2 infectivity or transmission, akin to what was seen for Spike
D614G (Korber et al., 2020; Volz, Hill, et al., 2021), which has overtaken the original
D614 form of the virus that dominated at the outset of the pandemic.
In areas where SARS-CoV-2 seroprevalence is high due to elevated rates of
transmission during primary waves of the pandemic, selection pressures may have
favored the emergence of variants that escape neutralizing antibodies. Such
circumstances are thought to have contributed to the rise of lineages B.1.351 and P.1
(501Y.V2 and 501Y.V3), which in addition to Spike N501Y, harbor at least two other
non-synonymous substitutions, K417N/T and E484K, which have been found to confer
escape from neutralizing antibodies (Weisblum, Schmidt, Zhang, DaSilva, Poston, J. C.
C. Lorenzi, et al., 2020; Cele et al., 2021; Liu et al., 2021; Wang et al., 2021).
Despite accounting for roughly 25% of globally recorded COVID-19 cases, and
approximately 20% of the available SARS-CoV-2 genome data, relatively few studies
have detailed the introduction and emergence of SARS-CoV-2 lineages in the United
States (Rochman et al., 2020; Worobey et al., 2020; Washington et al., 2021; Zeller et
al., 2021). Furthermore, seroprevalence surveys indicate that between 1 in 10 and 1 in
3 people in the USA have already been infected with SARS-CoV-2, potentially high
enough that selection for immune evasion may be ongoing (Angulo, Finelli and
Swerdlow, 2021; Bubar et al., 2021).
Variants affecting the Spike (S) protein are of great interest due to their potential to
impact transmissibility or to escape neutralizing antibodies developed in response to
natural infection or vaccines. A lineage carrying a D614G substitution quickly came to
dominate the pandemic (currently accounting for >98% of sequences)(Korber et al.,
2020), at least in part because this substitution promotes an S conformation that is more
competent for binding to angiotensin-converting enzyme 2 (ACE2) (Yurkovetskiy et al.,
2020) and reduces shedding of the S1 subunit that contains the receptor binding
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domain (Zhang et al., 2020). Missense mutations at other positions, for example S477N
and N439K, have appeared multiple times in large infection clusters in Australia and
Europe and are associated with resistance to certain antibodies and/or increased affinity
for ACE2 (Hodcroft et al., 2020; Liu et al., 2020; Weisblum, Schmidt, Zhang, DaSilva,
Poston, J. C. Lorenzi, et al., 2020; Gaebler et al., 2021; Thomson et al., 2021).
Here, we describe evidence from two independent SARS-CoV-2 genomic surveillance
programs in Louisiana and New Mexico that each detected the rise of S variants
affecting position 677 in the later months of 2020. We further provide phylogenetic
analyses that identify six independent Q677H sub-lineages and one Q677P sub-lineage
that all appear to have emerged within the United States. These variants were not
detected until mid-August 2020, but as of 03 Feb 2021 already account for over 2,327 of
the 102,462 genomes shared by USA based submitting and collecting authors via the
GISAID initiative (Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017). Given
the broad detection of the lineages across multiple states and the apparent increase in
their frequencies, these novel emergent Q677H and Q677P lineages merit further study
for potential differences in transmissibility.
Results.
In late January of 2021, our two independent SARS-CoV-2 genomic surveillance
programs, based at the University of New Mexico Health Sciences (UNM HSC) in
Albuquerque, New Mexico and the Louisiana State University Health Sciences Center
(LSUHS) in Shreveport, Louisiana, each noticed increasing numbers of PANGO lineage
B.1.2 (Rambaut et al., 2020) / Nextstrain clade 20G viruses carrying an S:Q677P
mutation, and that this variant had increased in frequency in samples collected in late
2020 to mid January (FIG. 1). We also noted broad but uneven geographical distribution
of these S: 677 polymorphic viruses across the United States, which approached 15%
of total viral sequences submitted since the beginning of the pandemic in certain states.
Given the proximity of this residue to the polybasic cleavage site (681-685), our
observations prompted communication between our two surveillance programs and
motivated us to carry out phylogenetic analyses of variation at S position 677.
Site frequency dynamics
In addition to the Q677P sub-lineage, our analyses indicated that SARS-CoV-2
variants carrying non-synonymous mutations affecting S codon 677 have arisen at least
six other times in the United States (FIG. 2, FIG. 3). Four of these occurred within clade
20G, a large clade that has accounted for over 30% of US sequences since October
2020, and as of the beginning of February 2021 represents approximately 50% of all
SARS-CoV-2 sequence data in the USA (Nextstrain Build, North America, Feb 04,
2021, 2021). The amino acid Q changes to H due to a mutation at nucleotide position
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23593. Notably, in four of these six lineages, the mutation changes from G to U,
whereas in the other two, it changes from G to C (FIG. 2). In contrast, the S:Q677P
variant occurs by virtue of an A to C change at position 23592. All mutations leading to
Q677H or Q677P involve transversions. Hence, their spontaneous occurrence is
generally disfavored relative to transitions. In SARS-CoV-2 samples from human
infections, A to C and G to C transversions occur at only ~10% the frequency of C to U
transitions, while G to U mutations are more common, occurring half as frequently as C
to U. (Wright, Lakdawala and Cooper, 2020) (Ratcliff and Simmonds, 2021). We also
note in GISAID data an S: Q677R cluster of 75 sequences caused by an A to G
transition at position 23592 (not shown). However, we focus here on the Q677P and
Q677H variants. For ease of discussion and to avoid using geographically-associated
names or nicknames, we have named each of the remaining seven S: 677 mutant
lineages identified here after American bird species.
Six U.S. lineages and a provisional naming system.
The largest of the 677 variant sub-lineages (“Robin 1”) is a B.1.2 / 20G clade
virus carrying Q677H that first appears in GISAID data from a sample with a August 17,
2020 collection date. As of Feb 4, 2021, this sub-lineage contained 754 sequences
(Table 1, FIG. 3). Robin 1 is found in over 30 US states, but predominates in the
Midwest. A second Q677H clade, distinguished from Robin 1 by an N2361K substitution
in orf1a, first appeared from a Oct 6, 2020 sample from Alabama and is named “Robin
2” owing to its similarity to the parental Robin 1 sub-lineage. This cluster contains 303
sequences, and is found mostly in the Southeast. Of note, a pre-print study recently
reported novel “20C-US” lineage, which includes Robin 1, and made mention of
S:Q677P and S:Q677R variants in the US (Pater et al., 2021).
The next largest cluster is the Q677P variant of 20G (B.1.2) (“Pelican”), which
was first detected in Oregon from a sample with collection date of Oct 23, 2020 and as
of Feb 3, 2021 contains 504 sequences. The Q677P variant has been detected in LA,
NM, NC, WY, MA, ID, MI AZ, CA, TX, WI, and MD, and five international sequences
(Australia (2), Denmark, Switzerland, India)(Emma B. Hodcroft, 2021). The remaining
Q677H sub-lineages each contain around 100 or fewer sequences, and are named:
Yellowhammer, detected mostly in the southeast US; Bluebird, mostly in the northeast
United States; Quail, mainly in the Southwest and Northeast; and Mockingbird, mainly in
the South-central and East coast states (Table 1, Fig. 3). A schematic summarizing the
key lineage-specific and shared protein polymorphisms of the US S: Q677P and
S:Q677H variants is shown in FIG 4.
Epidemiological details
Broad-scale genomic surveillance efforts conducted by the New Mexico Department of
Health (NM DOH) and the UNM HSC in December and January, 2021 revealed that 83
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of 733 SARS-CoV-2 genomes sequenced in New Mexico between December 1st and
January 19th contained the S:Q677P variant at a general frequency of 11.3% in the
SARS-CoV-2 positive individuals. In New Mexico, the S:Q677P substitution was first
observed from a December 12, 2020 sample, and its frequency among sequenced
viruses increased through January. In December 2020, our New Mexico-based
surveillance effort detected 23 genomes harboring the Q677P mutation, with an
additional 59 detected in January 2021. However, limited genomic sequencing of
positive cases in New Mexico in October and November hinder the ability to accurately
determine the true rate of increase.
Similarly, genomic surveillance efforts conducted by LSUHS together with the
Louisiana Department of Health first detected f the S:Q677P variant on Dec 1, 2020,
which over the month rose to 187 complete genomes, 150 of which were from a single,
large congregate facility outbreak. In part due to deep sampling of the large outbreak,
the Q677P virus amounted to 37.2% of all viral genomes sequenced from Dec 2020
samples collected in Louisiana (LSUHS submissions account for 481 of the 503 or
95.6% of the total SARS-CoV-2 genomes available on GISAID for the state with Dec
2020 collection dates). However, the Q677P variant also amounted to 14% of all
LSUHS samples collected in Jan 2021, and 11.4% of all Louisiana samples collected
between Jan 01 - Jan 19, 2021.
An S:Q677H variant was first detected from Louisiana in the summer of 2020, in
LSUHS samples collected on July 21, 2020 and Aug 11, 2020. Only 2 additional
S:Q677H sequences were collected from the entire state of Louisiana in Nov, both on
the 27th. Strikingly, however, the total for Dec 2020 rose to 53, amounting to 10.5% of
statewide sequence data for the month. According to the most recent LSUHS data,
which covers collection dates up to Jan 19, 2021, the Q677H polymorphism occurs in
5.7% of total SARS-CoV-2 genome data.
When considered in unison, S: Q677P and S: Q677H samples together comprise
47.5% of all Dec 2020 viral genomes collected from Louisiana, and 17.1% of the
genome sequences collected in the state from Jan 01 - 19, 2021. Acknowledging that
founder effects lead to stochastic fluctuations in the abundance of even neutral
genotypes, they also can contribute to the expansion of the fittest viruses. Thus, the
observation of a sudden and contemporaneous increase in the abundance of S: Q677H
and Q677P variants by surveillance programs in two different states along the southeast
/ southwest corridor is remarkable.
Modeled structure of variants
The S1/S2 cleavage site contains the multibasic cleavage site and is found in a
disordered region within Spike (S)(Wrapp et al., 2020). We used SWISS MODEL to
model this inherently flexible region and spotlight proline or histidine residues at position
677 (FIG. 5). Although the position 677 is outside the polybasic site (“furin binding
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pocket”) (Tian, Huajun and Wu, 2012), we speculate that the presence of a proline at
this site may introduce a favorable kink that promotes the dynamic conformational
changes necessary for cleavage at the S1/S2 junction, which is governed not only by
furin-like activities, but also by trypsin-like proteases (e.g., TMPRSS2) and cathepsins
(Jaimes, Millet and Whittaker, 2020). Moreover, the introduction of a proline in this
model appears to be 3.7 angstroms away from the carbon backbone of S689 (relative to
4.9 angstroms for the native glutamine), which may promote atomic interactions that
encourage conformations favorable for proteolytic cleavage. In the case of the S:
Q677H substitution, histidine protonation could similarly act as a conformational switch
affecting accessibility to proteases. Cleavage at the S1/S2 boundary promotes a more
‘open’ S conformation that is more competent to bind ACE2 (Wrobel et al., 2020), and
these putative mechanisms for enhanced cleavage at the S1/S2 junction may promote
more efficient viral entry (Hoffmann, Kleine-Weber and Pöhlmann, 2020).
Discussion.
Caveats.
Selectively neutral mutations can become fixed in a lineage purely by chance
and human behaviour. For instance, the 20E (EU1) lineage characterized by an S:
A222V polymorphism emerged suddenly in Europe over the summer, but thus far has
not shown evidence for increased transmissibility (Hodcroft et al., 2020) and instead is
thought to have been spread via holiday travel and relaxing summertime restrictions.
Additional S variants such as N439K and S477N also rapidly increased in frequency in
Europe over the summer and into the fall of 2020. Although S477N reportedly increases
affinity for the entry receptor, ACE2 (Zahradník et al., 2021), and both mutations may
impact antibody neutralization to some degree (Starr et al., 2020; Weisblum, Schmidt,
Zhang, DaSilva, Poston, J. C. Lorenzi, et al., 2020; Liu et al., 2021; Thomson et al.,
2021), neither shows any signature of increased transmissibility over the S: D614G
background from which they emerged, and neither have become prominent in the
United States. Therefore, SARS-CoV-2 variants can emerge and increase greatly in
number over time in the absence of any clear or sustained selective advantage.
Convergent evolution is a hallmark of positive selection.
The repeated evolution of a trait in independent populations provides strong
evidence of adaptation. Between August and November, 2020, seven independent
lineages of SARS-CoV-2 with S:Q677H or S:Q677P mutations arose and gained in
frequency. This coincidental rise and spread on independent genetic backgrounds is
remarkable and suggests some fitness advantage. Observed frequencies undoubtedly
incorporate some sampling biases, which may over-estimate the relative amount of S
variants affecting position 677. However, sampling bias cuts both ways. U.S. states with
fewer deposited sequences may simply have missed detection of these variants. To
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date, all 677H/P mutants collected from the US stem of the S:614G lineage that now
predominates worldwide, but alongside varied polymorphisms in S, N, ORF1a, ORF1b,
and other genes, suggesting any fitness advantage of S:677 mutations is largely
independent of these other mutations (Table 1, FIG. 2-4). Nonetheless, the relatively
slow rise of lineages with S:677 substitutions suggest that any fitness benefits may be
modest relative to other circulating variants, which may have also independently gained
adaptive mutations. Given their relatively recent emergence, however, Q677P/H
lineages may continue to rise as a percentage of total cases. Additional laboratory and
genetic surveillance data are needed to define whether S: 677 polymorphisms are
biologically and clinically relevant.
Although we focus here on the appearance and expansion of S: 677H/P mutants
in the United States, global analyses reveal that 677H mutants have arisen multiple
times elsewhere in the world as well, including large clusters of 677H mutants in Egypt
and Denmark, and multiple clusters in India (Emma B. Hodcroft, 2021). Furthermore, a
newly designated, emergent PANGO lineage, B.1.525, carries S: Q677H in addition to
several mutations seen in B.1.1.7 (501Y.V1), such as S: del 69-70 and S: del 144, and
also, S: E484K (Rambaut et al., 2020; Áine O’Toole, 2021). Remarkably, a 19B cluster
harboring the ostensibly less fit, ‘ancestral’ D614 Spike, which has been circulating at
≤2% of global frequency since August 2020, recently resurfaced as a newly reemergent lineage carrying N501Y together with 677H(Wagner, 2021). N501Y is
therefore notable for being found in all three “variants of concern” (Tegally et al., 2020;
Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in
the EU/EEA – first update, 2021; Faria et al., 2021; Galloway et al., 2021; Lauring and
Hodcroft, 2021; Naveca, Nascimento, et al., 2021; Volz, Mishra, et al., 2021).
Acknowledging this observation is circumstantial, it further suggests that the 677H
mutation may confer an evolutionary advantage to SARS-CoV-2, just as substitutions
affecting S positions 417, 484, and 501 have emerged as examples of parallelism in
multiple ‘variant of concern’ lineages (Andrew Rambaut, Nick Loman, Oliver Pybus,
Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L
Robertson, Erik Volz, COVID-19 Genomics Consortium UK (CoG-UK), 2020; Tegally et
al., 2020; Naveca, Nascimento, et al., 2021; Resende et al., 2021).
The importance of sequencing for viral surveillance and genomic epidemiology.
Global surveillance of genomic changes in SARS-CoV-2 varies widely, with
leading countries such as Australia, New Zealand, the United Kingdom, and Denmark
sequencing viruses from 5-50% of all cases and lagging countries such as the United
States, France, Spain, and Brazil sequencing less than 1% of all cases. It is notable that
these Q677 variants were detected in the undersampled US population, suggesting that
these lineages may actually be more prevalent. The finding of lineages containing 677H
mutations in better sampled countries like Denmark indicates that they repeatedly
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emerge but may be outcompeted by lineages with larger gains in transmission like
B.1.1.7 (Davies et al., 2020). Collectively, these findings demonstrate the value of
greater genomic sequencing and the importance of tracking the emergence and spread
of lineages that combine multiple mutations which could enhance transmissibility or
evade immunity from prior infection or vaccines.
At least two emergent lineages of concern, B.1.1.7 (501Y.V1), and a newer
variant whose prevalence is on the rise in Uganda both contain amino acid substitutions
affecting the first position of the polybasic cleavage site, S:P681H and S:P681R,
respectively (Andrew Rambaut, Nick Loman, Oliver Pybus, Wendy Barclay, Jeff Barrett,
Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz, COVID19 Genomics Consortium UK (CoG-UK), 2020; Lule Bugembe et al., 2021). The
polybasic site strongly impacts viral replication in culture and as well as pathogenesis in
animal models (Hoffmann, Kleine-Weber and Pöhlmann, 2020; Johnson et al., 2021).
Although it is too early to predict whether any particular S: 677 polymorphic lineages will
persist, given these observations, the recurrent parallelism affecting S: 677 suggests
that this position will continue to surface in variants that show signs of increased
transmissibility or fitness. It will be critical to continue genomic surveillance of SARSCoV-2 to monitor the prevalence of such variants over time, as well as formally define
any biological characteristics of these polymorphisms in cell culture and small animal
model systems.
Methods.
Sequencing.
Genome sequencing of SARS-CoV-2 at the UNM HSC was conducted from RNA
isolated from residual clinical specimens that had previously been determined to be
positive for SARS-CoV-2 by FDA-approved diagnostic testing. SARS-CoV-2 genomic
sequences were amplified by PCR using the widely adopted ARTIC primer set (v3) and
were sequenced either on an Illumina MiSeq or Oxford Nanopore GridION system using
in-house, slightly modified versions of protocols (https://www.protocols.io/view/sars-cov2-illumina-miseq-protocol-v-1-bjd9ki96 & https://www.protocols.io/view/ncov-2019sequencing-protocol-v3-locost-bh42j8ye), respectively.
For LSUHS samples, SARS-CoV-2 genomic RNA sequencing was done as follows. 13
µL of de-identified total RNA from patient anterior turbinate nasal swabs previously
determined as SARS-CoV-2 positive CDC N1 / N2 RT-PCR assay results of Ct <26,
was subjected to hybridization capture enrichment sequencing. For each sample, 13µL
of extracted RNA was reverse transcribed using Maxima H-minus ds cDNA kits
(ThermoFisher Scientific). Libraries were enriched using a Nextera Flex for Enrichment
Library Preparation kit with a Respiratory Virus Oligo Set v2, with samples being pooled
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in 12-plex enrichment reactions, essentially as described elsewhere (O’Flaherty et al.,
2018). The resulting pools were quantified and grouped in sets of no more than 48
samples and run on a NextSeq 550 using a 150cyc High Output Flow Cell. We used
breseq (Deatherage and Barrick, 2014) (v.0.34.1) to map reads to Wuhan-Hu-1 SARSCoV-2 (NC_045512) or 2019-nCoV WIV04 (GISAID EPI_ISL_402124, NCBI Genbank
MN996528)(Zhou et al., 2020) and call the consensus sequence. All predicted
mutations were reported for isolates exceeding mean 40x coverage.
Phylogenetic analyses.
A ‘focal’ Nextstrain build of 5874 sequences was prepared as described in Hodcroft et
al, 2020, initially selecting for sequences with any mutation at position 23592 or 23593.
These sequences are used as a ‘focal set’ around which background sequences are
selected, capturing both the sequences most genetically similar to the focal set, as well
as a selection of sequences distributed across time and by country. Both of these are
then processed through the open-source Nextstrain `ncov` pipeline to produce a timeresolved phylogenetic analysis. A time-stamped version of the Nextstrain build used in
this manuscript can be found here:
https://nextstrain.org/groups/neherlab/ncov/S.Q677/2020-02-04, and the most recently
updated version of this build can be viewed here:
https://nextstrain.org/groups/neherlab/ncov/S.Q677. The final designations of the
clusters and counts of sequences within them were determined from the resulting
phylogenetic tree rather than the ‘raw counts’ from on the nucleotide mutations given
above, as the phylogenetic structure can better account for gaps and reversions in
sequences which might prevent a sequence being picked up by mutations alone. The
resulting JSON file from the Nextstrain pipeline was used to visualize the phylogenetic
trees using the baltic package (https://github.com/evogytis/baltic). A full table of
acknowledgements for the data included in this analysis is available in the supplement.
Structural analyses and sequence alignments.
SWISS-MODEL(Bienert et al., 2017; Waterhouse et al., 2018) was used to model the
full length, wild type and Q677P mutant spike glycoprotein. The template utilized for the
model was 7BBH (Wrobel, A.G., Benton, D.J., Rosenthal, P.B., Gamblin, S.J., 2020),
which has all receptor binding domains in the down conformation. The entire furin
cleavage site for the D614G ("WT") and D614G+Q677P (mutant) version of the SARSCoV-2 Spike, based on PDB . PyMol 2.4 (Schödinger, Inc.) was subsequently used to
superimpose the resulting structures and highlight the side chains of each individual
structure.
Translation alignment of S:Q677 variants was done using Geneious version 2021.0
(Biomatters Limited, Auckland, NZ).
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FIGURE LEGENDS.
Figure 1. Rising prevalence of SARS-CoV-2 S:Q677P and S:Q677H variants in the
United States. (A) Monthly number of Q677H and Q677P variant viruses in the USA
and worldwide found in GISAID data. Note that data for samples collected in December
and January are incomplete for many surveillance facilities. (B) State-by-state
prevalence of United States Q677H and Q677P variants (percent frequency shaded
from 0%- 15% out of total GISAID data up to Feb 03, 2021).
Figure 2. Newly emergent SARS-CoV-2 spike position 677 variants. (A) A simplified
Nextstrain phylogeny of 677H and 677P lineages. (B) A nucleotide and protein
alignment of representative S genes from Q677P 92C, and Q677H 93U, Q677H 93C
lineages, set against the reference sequence: Dec 2019 Wuhan, China, WIV04
(GISAID: EPI_ISL_402124, GenBank: MN996528). The polybasic or “furin” cleavage
site is labeled, as are the portions of the S1 and S2 subunits pictured in the alignment.
Figure 3. Time-scaled phylogeny of recently expanded United States S:677 variant
lineages in their international context. A ‘focal’ Nextstrain build was prepared initially
selecting for sequences with any mutation at position 23592 or 23593. These
sequences were used as a ‘focal set’ around which background sequences are
selected, capturing both the sequences most genetically similar to the focal set, as well
as a selection of sequences distributed across time and by country. Red and blue
indicate Q677H and Q677P viral genome sequences, as indicated in the legend. USA
‘bird’ lineages are specifically labeled among global data for S:677 variants represented
in the build. A full table of acknowledgements for the data included in this analysis is
available in the supplement.
Figure 4. Lineage-specific and shared amino acid polymorphisms of US S:Q677P
and S:677H variants. The U.S. S:Q677P and S:Q677H variants defined in Figs.1-2 are
illustrated for the major defining protein variants that are shared among most or all of
the viruses (pink), or restricted to one (green) or two (yellow). Q677P and Q677H
polymorphisms are shown in bold and in red.
Figure 5. Structure of SARS-CoV-2 Spike protein denoting location of Q677P and
Q677H within a disordered loop adjacent to the polybasic (furin) cleavage site.
Structure was modeled from PDB: 7BBH using SWISS-MODEL and visualized using
PyMol. 677P is shown in red and 677H in green.
Table 1. Genetic attributes and relative abundance of six different SARS-CoV-2
lineages identified by S:Q677 mutations.
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Figure 1. Rising prevalence of SARS-CoV-2 S:Q677P and S:Q677H variants in the
United States. (A) Monthly number of Q677H and Q677P variant viruses in the USA
and worldwide found in GISAID data. Note that data for samples collected in December
and January are incomplete for many surveillance facilities. (B) State-by-state
prevalence of United States Q677H and Q677P variants (percent frequency shaded
from 0%- 15% out of total GISAID data up to Feb 03, 2021).
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Figure 2. Newly emergent SARS-CoV-2 spike position 677 variants. (A) A simplified
Nextstrain phylogeny of 677H and 677P lineages. (B) A nucleotide and protein
alignment of representative S genes from Q677P 92C, and Q677H 93U, Q677H 93C
lineages, set against the reference sequence: Dec 2019 Wuhan, China, WIV04
(GISAID: EPI_ISL_402124, GenBank: MN996528). The polybasic or “furin” cleavage
site is labeled, as are the portions of the S1 and S2 subunits pictured in the alignment.
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Figure 3. Time-scaled phylogeny of recently expanded United States S:677 variant
lineages in their international context. A ‘focal’ Nextstrain build was prepared initially
selecting for sequences with any mutation at position 23592 or 23593. These
sequences were used as a ‘focal set’ around which background sequences are
selected, capturing both the sequences most genetically similar to the focal set, as well
as a selection of sequences distributed across time and by country. Red and blue
indicate Q677H and Q677P viral genome sequences, as indicated in the legend. USA
‘bird’ lineages are specifically labeled among global data for S:677 variants represented
in the build. A full table of acknowledgements for the data included in this analysis is
available in the supplement.
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Figure 4. Lineage-specific and shared amino acid polymorphisms of US S:Q677P
and S:677H variants. The U.S. S:Q677P and S:Q677H variants defined in Figures 2-3
are illustrated for the major defining protein variants that are shared among most or all
of the viruses (pink), or restricted to one (green) or two (yellow). Q677P and Q677H
polymorphisms are shown in bold and in red. A full table of acknowledgements for the
data included in this analysis is available in the supplement.
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Figure 5. Structure of SARS-CoV-2 Spike protein denoting location of Q677P and
Q677H within a disordered loop adjacent to the polybasic (furin) cleavage site.
Structure was modeled from PDB: 7BBH using SWISS-MODEL and visualized using
PyMol. 677P is shown in red and 677H in green.
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M2606I
L3352F
P67S
P199L*

Q57H
G172V
T265I
L3352F
Q3729R

Q57H
G172V
T265I
M2606I
L3352F
A3454V
P67S
P199L*
A376V
E378Q
P314L
N1653D
P1666L
R2613C
USA/AL-HGSCJFBB/2020

T29I
T572I
D614G
Q677H
D936N
S58N
H78Y

R203K
G204R
M234I

R203K
G204R

S194L
T391I

P314L

P314L

P314L

USA/CT-Yale352/2020

USA/NYMSHSPSPPV19649/2020

USA/TX-HMHMCoV18986/2020

N

P67S
P199L*
D377Y

ORF1b

P314L
N1653D
R2613C

Example
sequence near
clade root

USA/WI-UW2237/2020

P314L
T1555I (many)
N1653D
R2613C
USA/ALCullmanJEMT/2020

P67S
P199L*
N:M210I
(many)
P314L
N1653D
R2613C
USA/TX-HMHMCoV19011/2020

V665I
K2059R
D2980G
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Defining
mutation
Lineage
(Nextstrain /
pangolin)
Approximate
date of origin
Deposited
sequences
S

667H
“Robin1”
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* shared on recent common ancestor within 20G / B.1.2
** T732A occurs on a branch prior to the MRCA of Quail, then A732S occurs on a branch inside of Quail, with only 2 sequences
inside the cluster not carrying this mutation.

